Los Angeles Capital Management LLC Verve Therapeutics, Inc. Transaction History

Los Angeles Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 06, 2025	SELL	$2.97 - $11.38 $109,459 - $419,409	-36,855 Reduced 34.79%	69,083 $775,000
Q1 2025 May 05, 2025	SELL	$4.57 - $8.63 $572,095 - $1.08 Million	-125,185 Reduced 54.16%	105,938 $484,000
Q4 2024 Feb 04, 2025	SELL	$4.5 - $7.19 $140,715 - $224,831	-31,270 Reduced 11.92%	231,123 $1.3 Million
Q3 2024 Nov 04, 2024	BUY	$4.4 - $7.86 $87,670 - $156,610	19,925 Added 8.22%	262,393 $1.27 Million
Q2 2024 Aug 05, 2024	BUY	$4.76 - $12.79 $1.15 Million - $3.1 Million	242,468 New	242,468 $1.18 Million

Q2 2022 Aug 05, 2022	SELL	$11.14 - $23.17 $185,870 - $386,591	-16,685 Closed	0 $0
Q1 2022 May 06, 2022	BUY	$20.92 - $39.36 $349,050 - $656,721	16,685 New	16,685 $381,000

8.51M

2.9K

37.1K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $667M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Los Angeles Capital Management LLC with notifications on news.